Moexipril盐酸莫西普利,82586-52-5

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Moexipril hydrochloride

CAS No. : 82586-52-5

MCE 国际站：Moexipril hydrochloride

产品活性：Moexipril hydrochloride (RS-10085) 是一种具有口服活性的血管紧张素转换酶 (ACE) 抑制剂，经水解为 moexiprilat 而发挥活性。Moexipril hydrochloride 具有降压和神经保护作用。

研究领域：Metabolic Enzyme/Protease  |  Apoptosis

作用靶点：Angiotensin-converting Enzyme (ACE)  |  Apoptosis

In Vitro: Moexipril hydrochloride is devoid of anti-inflammatory properties and has no effect on platelet function.
Moexipril hydrochloride hydrolyzes to Moexiprilat, and Moexiprilat inhibits ACE in guinea pig serum as well as on purified ACE from rabbit lung with IC₅₀s of 2.6 and 4.9 nM, respectively.
Moexipril hydrochloride (0.01 nM-0.1 mM) exhibits high potency against both plasma ACE and purified ACE from rabbit lung, with IC₅₀s of 2.7 mM and 0.165 mM, respectively.
Moexipril hydrochloride (0-100 μM, 24 h) significantly reduced the percentage of damaged neurons in a dose-dependent manner.
Moexipril hydrochloride (0-100 μM, 24 h) significantly attenuates Fe^2+/3+-induced neurotoxicity.
Moexipril hydrochloride dose not cause significant changes in the percentage of apoptotic neurons.

In Vivo: Moexipril hydrochloride can not cross the blood-brain barrier.
Moexipril hydrochloride (3 mg/kg, 30 mg/kg and 10 mg/kg, respectively; p.o.; once daily; 5 days) exhibits the a dose-dependent and antihypertensive effects in renal hypertensive rats, spontaneously hypertensive rats and perinephritic hypertensive dogs, respectively.
Moexipril hydrochloride (0.3 mg/kg, i.p.) significantly reduces the infarct area on the mouse brain surface in NMRI mice.
Moexipril hydrochloride (0.1 mg/kg, i.p.) significantly attenuates the cortical infarct volume in Long-Evans rats.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Peptidomimetic Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Neuroprotective Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Angiogenesis-Related Compound Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Antihypertensive Compound Library  |  Membrane Protein-targeted Compound Library  |  Cell Death Library  |  MG-132  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Staurosporine  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  Gemcitabine  |  Temozolomide  |  Rotenone  |  Mdivi-1  |  Elesclomol  |  Ruxolitinib  |  Decitabine  |  SP600125  |  MK-2206 dihydrochloride  |  Etoposide  |  Monomethyl auristatin E

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds